Navigation Links
Transitioning epithelial cells to mesenchymal cells enhances cardiac protectivity

Putnam Valley, NY. (Dec. 23, 2013) Cell-based therapies have been shown to enhance cardiac regeneration, but autologous (patient self-donated) cells have produced only "modest results." In an effort to improve myocardial regeneration through cell transplantation, a research team from Germany has taken epithelial cells from placenta (amniotic epithelial cells, or AECs) and converted them into mesenchymal cells. After transplanting the transitioned cells into mice modelling a myocardial infarction, the researchers found that the epithelial-to-mesenchymal transition (EMT) was beneficial to cardiac regeneration by lowering infarct size. They concluded that EMT enhanced the cardioprotective effects of human AECs.

The study will be published in a future issue of Cell Transplantation but is currently freely available on-line as an unedited early e-pub at:

The authors noted that AECs have been shown to share characteristics of pluripotent cells that are able to transform into all other kinds of cells, and that their isolation and clinical-grade expansion of AECs is "relatively straightforward."

"Our hypothesis was that EMT would improve cardiac regeneration capacity of amniotic epithelial cells by increasing their mobility and extracellular matrix modulating capacity," said study corresponding author Dr. Christof Stamm of the Berlin Brandenburg Center for Regenerative Therapies, Berlin, Germany. "Indeed, four weeks after the mice were modeled with myocardial infarction the mice subsequently treated with EMT-AECs were associated with markedly reduced infarct size."

According to the researchers, as a result of the EMT process the AECs lost their "cobblestone" structure and acquired a fibroblastoid shape which was associated with a number of biological alterations that ultimately aided their mobility and altered their secretions.

One direct result of the EMT-AEC treatment was that EMT-AEC-treated hearts displayed "better global systolic function and improved longitudinal strain rate in the area of interest."

The researchers added that while AECs may be useful in the context of cardiovascular regeneration, it is unclear whether the usefulness requires "actual stemness" or "pluripotency-unrelated secretory mechanisms."

"Blood vessel density was increased in both AEC and EMT-AEC-treated hearts and we conclude that EMT enhances the cardioprotective effects of human AECs," they wrote.

"This study highlights how AECs are a potentially useful stem cell population whose use can be maximized by a transformation, such as EMT, prior to transplantation" said Dr Amit N. Patel, director of cardiovascular regenerative medicine at the University of Utah and section editor for Cell Transplantation. "This was demonstrated in a myocardial infarction model but further study is necessary to confirm whether this transformation is relevant for other diseases (and other cell types)".


Contact: Robert Miranda
Cell Transplantation Center of Excellence for Aging and Brain Repair

Related biology news :

1. Young adults with autism found to have difficulty transitioning into employment
2. A flip of the mitotic spindle has disastrous consequences for epithelial cells
3. How the cells remove copper
4. Enlisting cells protein recycling machinery to regulate plant products
5. Liver cells benefit from mesenchymal stem cell co-culture prior to transplantation
6. Preferable treatment for MS found in allogenic bone marrow stem cells
7. Scientists find a groovy way to influence specialization of stem cells
8. Muscle-invasive and non-muscle invasive bladder cancers arise from different stem cells
9. New hope for stem cells, regenerative medicine emerges from the lab
10. Microprinting leads to low-cost artificial cells
11. Researchers engineer a hybrid 5 times more effective in delivering genetic material into cells
Post Your Comments:
(Date:11/9/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), the ... entry into the automotive market with a comprehensive and ... of consumer electronics human interface innovation. Synaptics, industry-leading touch ... the automotive industry and will be implemented in numerous ... , Japan , and ...
(Date:11/2/2015)... PARK, Calif. , Nov. 2, 2015  SRI ... $9 million to provide preclinical development services to the ... the contract, SRI will provide scientific expertise, modern testing ... wide variety of preclinical pharmacology and toxicology studies to ... --> The PREVENT Cancer Drug Development ...
(Date:10/29/2015)... Calif. , Oct. 29, 2015  The J. ... new report titled, "DNA Synthesis and Biosecurity: Lessons Learned ... the Department of Health and Human Services guidance for ... in 2010. --> ... it also has the potential to pose unique biosecurity ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... Studies reveal the differences in species of ... way for more effective treatment for one of the most ... --> --> Gum disease is ... yet relatively little was understood about the bacteria associated with ... by researchers from the WALTHAM Centre for Pet Nutrition together ...
(Date:11/25/2015)... Orexigen® Therapeutics, Inc. (Nasdaq: OREX ) ... chat discussion at the Piper Jaffray 27th Annual Healthcare ... discussion is scheduled for Wednesday, December 2, at 8:00 ... replay will be available for 14 days after the ... NormartVP, Corporate Communications and Business Development , BrewLife(858) 875-8629 ...
(Date:11/24/2015)... -- Cepheid (NASDAQ: CPHD ) today announced that ... and invited investors to participate via webcast. ... 1, 2015 at 11.00 a.m. Eastern Time --> ... 1, 2015 at 11.00 a.m. Eastern Time --> ... NY      Tuesday, December 1, 2015 at 11.00 ...
(Date:11/24/2015)... , Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... IIROC on behalf of the Toronto Stock Exchange, confirms ... there are no corporate developments that would cause the ... --> --> About Aeterna Zentaris ... . --> Aeterna Zentaris is a specialty ...
Breaking Biology Technology: